Bioinformatics and HIV Latency

Current HIV/AIDS Reports

Volumn 12, Issue 1, 2015, Pages 97-106

  Ciuffi, Angela ^a   Mohammadi, Pejman ^a   Golumbeanu, Monica ^b,c   di Iulio, Julia ^d   Telenti, Amalio ^e  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d HARVARD MEDICAL SCHOOL   (United States)

^e J CRAIG VENTER INSTITUTE   (United States)

Author keywords

Bioinformatics; HIV; Integration; Latency; Proteome; Transcription; Transcriptome

Indexed keywords

PROTEOME; TRANSCRIPTOME;

BIOINFORMATICS; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PROTEIN ANALYSIS; REVIEW; VIRUS GENOME; VIRUS LATENCY; BIOLOGY; HUMAN; PHYSIOLOGY; PROCEDURES;

COMPUTATIONAL BIOLOGY; HIV; HUMANS; VIRUS LATENCY;

EID: 84925486198     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0240-x     Document Type: Review

References (100)

1. Siliciano JD, Siliciano RF. The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr Opin HIV AIDS. 2006;1:121–8.
2. Durand CM, Blankson JN, Siliciano RF. Developing strategies for HIV-1 eradication. Trends Immunol. 2012;33:554–62. Excellent review and overview of the obsacle of the HIV reservoir and the strategies to eliminate it.
3. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345:169–74.
4. Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM. Prospects for treatment of latent HIV. Clin Pharmacol Ther. 2013;93:46–56.
5. Abou-El-Enein M, Bauer G, Reinke P, Renner M, Schneider CK. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med. 2014;20(11):632–42.
6. Kent SJ, Reece JC, Petravic J, Martyushev A, Kramski M, De Rose R, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis. 2013;13:614–21.
7. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7:798–812.
8. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512:74–7. This study shows that upon viral infection the viral reservoir is established very early (in less than three days) in an animal model. This study also shows that HIV is detectable in lymph nodes but not in blood of some animals, suggesting that lymph nodes may be an early and important reservoir.
9. Zaikos TD, Collins KL. Long-lived reservoirs of HIV-1. Trends Microbiol. 2014;22:173–5.
10. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37:377–88.
11. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology. 2009;6:51.
12. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014;111:2307–12.
13. Costiniuk CT, Jenabian MA. Cell-to-cell transfer of HIV infection: implications for HIV viral persistence. J Gen Virol. 2014;95:2346–55.
14. Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS. 2014;9:552–8.
15. Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 2014;10:e1003872.
16. Soriano-Sarabia N, Bateson RE, Dahl NP, Crooks AM, Kuruc JD, Margolis DM, et al. The quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J Virol. 2014; 88:14070-7.
17. Kumar A, Abbas W, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses. 2014;6:1837–60.
18. Bacchus C, Cheret A, Avettand-Fenoel V, Nembot G, Melard A, Blanc C, et al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS ONE. 2013;8:e64219.
19. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis. 2014;210:728–35.
20. Nixon CC, Vatakis DN, Reichelderfer SN, Dixit D, Kim SG, Uittenbogaart CH, et al. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood. 2013;122:2195–204.
21. McNamara LA, Onafuwa-Nuga A, Sebastian NT, Riddell J, Bixby D, Collins KL. CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression. J Infect Dis. 2013;207:1807–16.
22. Narasipura SD, Kim S, Al-Harthi L. Epigenetic regulation of HIV-1 latency in astrocytes. J Virol. 2014;88:3031–8.
23. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak Jr M, Coffin JM, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2014;111:7078–83. This study measured the fraction of the inducible reservoir upon exposure to different conditions.
24. Pace MJ, Agosto L, Graf EH, O’Doherty U. HIV reservoirs and latency models. Virology. 2011;411:344–54.
25. Hakre S, Chavez L, Shirakawa K, Verdin E. HIV latency: experimental systems and molecular models. FEMS Microbiol Rev. 2012;36:706–16.
26. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 2013;9:e1003834. A comparative study of different HIV latency cell models and their response to multiple latency reactivating agents or stimuli.
27. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 2013;21:277–85.
28. Archin NM, Margolis DM. Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis. 2014;27:29–35.
29. Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today. 2013;18:541–51.
30. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013;9:e1003174. A comparative study of different methods to estimate the size of the viral reservoir.
31. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155:540–51. This study quantified the proportion of HIV+ cells carrying defective versus replication-competent proviral sequences.
32. Mohammadi P, di Iulio J, Munoz M, Martinez R, Bartha I, Cavassini M, et al. Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog. 2014;10:e1004156. This study characterized the joint viral and cellular transcriptome in a latency model over time. Post-transcriptional block and cellular activation status were identified as components of latency.
33. Papayannakos C, Daniel R. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. Gene Ther. 2013;20:581–8.
34. Ciuffi A, Bushman F: Retroviral integration target site selection. In: HIV-1 integrase: mechanism of action and inhibitor design. edn 1. Edited by Neamati N: John Wiley & Sons, Inc.; 2011:51–65. [Binghe W (Series Editor): Wiley Series in Drug Discovery and Development
35. Desfarges S, Ciuffi A: Viral integration and consequences on host gene expression. In: Viruses: essential agents of life. Edited by Witzany G: Springer Science + Business Media; 2012.
36. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther. 2008;8:419–29.
37. Desfarges S, Ciuffi A. Retroviral integration site selection. Viruses. 2010;2:111–30.
38. Ciuffi A, Telenti A. State of genomics and epigenomics research in the perspective of HIV cure. Curr Opin HIV AIDS. 2013;8:176–81.
39. Ciuffi A, Barr SD. Identification of HIV integration sites in infected host genomic DNA. Methods. 2011;53:39–46.
40. Ciuffi A, Ronen K, Brady T, Malani N, Wang G, Berry CC, et al. Methods for integration site distribution analyses in animal cell genomes. Methods. 2009;47:261–8.
41. Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med. 2009;15:1431–6.
42. Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, et al. HIV latency and integration site placement in five cell-based models. Retrovirology. 2013;10:90. A comparative study of latency models to identify genomic features of integration site locations specific of HIV latency.
43. Firouzi S, Lopez Y, Suzuki Y, Nakai K, Sugano S, Yamochi T, et al. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. Genome Med. 2014;6:46.
44. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014;345:179–83. This study identified clonal expansion of some infected cells in HIV+ individuals.
45. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345:570–3. This study identified clonal expansion of some infected cells in HIV+ individuals.
46. Margolis D, Bushman F. HIV/AIDS. Persistence by proliferation? Science. 2014;345:143–4.
47. Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med. 2014;20:139–42.
48. Powers JM, Trobridge GD. Identification of hematopoietic stem cell engraftment genes in gene therapy studies. J Stem Cell Res Ther. 2013;2013.
49. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology. 2013;10:67.
50. Mbonye U, Karn J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology. 2014;454–455:328–39.
51. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, Hannenhalli S, et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol. 2005;79:6610–9.
52. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, et al. Directly infected resting CD4+ T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog. 2012;8:e1002818.
53. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol. 2004;78:6122–33.
54. Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Irizarry RA, et al. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol. 2011;85:5384–93.
55. Dahabieh MS, Ooms M, Brumme C, Taylor J, Harrigan PR, Simon V, et al. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFkappaB. Retrovirology. 2014;11:17.
56. Ghazalpour A, Bennett B, Petyuk VA, Orozco L, Hagopian R, Mungrue IN, et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet. 2011;7:e1001393.
57. Low TY, van Heesch S, van den Toorn H, Giansanti P, Cristobal A, Toonen P, et al. Quantitative and qualitative proteome characteristics extracted from in-depth integrated genomics and proteomics analysis. Cell Rep. 2013;5:1469–78.
58. Fu X, Fu N, Guo S, Yan Z, Xu Y, Hu H, et al. Estimating accuracy of RNA-Seq and microarrays with proteomics. BMC Genomics. 2009;10:161.
59. Bentley DL. Coupling mRNA processing with transcription in time and space. Nat Rev Genet. 2014;15:163–75.
60. Groen JN, Capraro D, Morris KV. The emerging role of pseudogene expressed non-coding RNAs in cellular functions. Int J Biochem Cell Biol. 2014;54:350–5.
61. Groen JN, Morris KV. Chromatin, non-coding RNAs, and the expression of HIV. Viruses. 2013;5:1633–45.
62. Swaminathan S, Kelleher AD. MicroRNA modulation of key targets associated with T cell exhaustion in HIV-1 infection. Curr Opin HIV AIDS. 2014;9:464–71.
63. Chiang K, Rice AP. MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses. 2012;4:1390–409.
64. Fowler L, Saksena NK. Micro-RNA: new players in HIV-pathogenesis, diagnosis, prognosis and antiviral therapy. AIDS Rev. 2013;15:3–14.
65. Swaminathan G, Navas-Martin S, Martin-Garcia J. MicroRNAs and HIV-1 infection: antiviral activities and beyond. J Mol Biol. 2014;426:1178–97.
66. Cox JE, Sullivan CS. Balance and stealth: the role of noncoding RNAs in the regulation of virus gene expression. Ann Rev Virol. 2014;1:89–109.
67. Saayman S, Ackley A, Turner AM, Famiglietti M, Bosque A, Clemson M, et al. An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription. Mol Ther. 2014;22:1164–75.
68. Chang H, Lim J, Ha M, Kim VN. TAIL-seq: genome-wide determination of poly(A) tail length and 3′ end modifications. Mol Cell. 2014;53:1044–52.
69. Weake VM, Workman JL. Inducible gene expression: diverse regulatory mechanisms. Nat Rev Genet. 2010;11:426–37.
70. Voss TC, Hager GL. Dynamic regulation of transcriptional states by chromatin and transcription factors. Nat Rev Genet. 2014;15:69–81.
71. Ocwieja KE, Brady TL, Ronen K, Huegel A, Roth SL, Schaller T, et al. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog. 2011;7:e1001313.
72. Imbeault M, Giguere K, Ouellet M, Tremblay MJ. Exon level transcriptomic profiling of HIV-1-infected CD4(+) T cells reveals virus-induced genes and host environment favorable for viral replication. PLoS Pathog. 2012;8:e1002861.
73. Wan Y, Qu K, Zhang QC, Flynn RA, Manor O, Ouyang Z, et al. Landscape and variation of RNA secondary structure across the human transcriptome. Nature. 2014;505:706–9.
74. Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology. 2013;10:11.
75. Lusic M, Giacca M. Regulation of HIV-1 latency by chromatin structure and nuclear architecture. J Mol Biol. 2014. doi:10.1016/j.jmb.2014.07.022.
76. Park J, Lim CH, Ham S, Kim SS, Choi BS, Roh TY. Genome-wide analysis of histone modifications in latently HIV-1 infected T cells. AIDS. 2014;28:1719–28.
77. Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, et al. Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. Mol Cell Biol. 2014;34:1911–28.
78. Evans VA, Kumar N, Filali A, Procopio FA, Yegorov O, Goulet JP, et al. Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog. 2013;9:e1003799.
79. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007;316:1484–8.
80. Yang L, Duff MO, Graveley BR, Carmichael GG, Chen LL. Genomewide characterization of non-polyadenylated RNAs. Genome Biol. 2011;12:R16.
81. Marzluff WF, Wagner EJ, Duronio RJ. Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. Nat Rev Genet. 2008;9:843–54.
82. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog. 2006;2:e68.
83. Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature. 2014;509:575–81.
84. Zhang L, Zhang X, Ma Q, Zhou H. Host proteome research in HIV infection. Genom, Proteome Bioinforma. 2010;8:1–9.
85. Zhu J, Davoli T, Perriera JM, Chin CR, Gaiha GD, John SP, et al. Comprehensive identification of host modulators of HIV-1 replication using multiple orthologous RNAi reagents. Cell Rep. 2014;9:752–66.
86. Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med. 2012;2:a006940.
87. DeBoer J, Jagadish T, Haverland NA, Madson CJ, Ciborowski P, Belshan M. Alterations in the nuclear proteome of HIV-1 infected T-cells. Virology. 2014;468-470:409–20.
88. Haverland NA, Fox HS, Ciborowski P. Quantitative proteomics by SWATH-MS reveals altered expression of nucleic acid binding and regulatory proteins in HIV-1-infected macrophages. J Proteome Res. 2014;13:2109–19.
89. Greco TM, Diner BA, Cristea IM. The impact of mass spectrometry-based proteomics on fundamental discoveries in virology. Ann Rev Virol. 2014;1:581–604.
90. Weekes MP, Tomasec P, Huttlin EL, Fielding CA, Nusinow D, Stanton RJ, et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell. 2014;157:1460–72.
91. Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2013;14:35–48.
92. Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, et al. Global landscape of HIV-human protein complexes. Nature. 2012;481:365–70.
93. Navare AT, Sova P, Purdy DE, Weiss JM, Wolf-Yadlin A, Korth MJ, et al. Quantitative proteomic analysis of HIV-1 infected CD4+ T cells reveals an early host response in important biological pathways: protein synthesis, cell proliferation, and T-cell activation. Virology. 2012;429:37–46.
94. Wojcechowskyj JA, Didigu CA, Lee JY, Parrish NF, Sinha R, Hahn BH, et al. Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry. Cell Host Microbe. 2013;13:613–23. This paper is the first phosphoproteomic study in a natural infection design, i.e. X4-tropic HIV on primary CD4+ T cells.
95. Pan X, Baldauf HM, Keppler OT, Fackler OT. Restrictions to HIV-1 replication in resting CD4+ T lymphocytes. Cell Res. 2013;23:876–85.
96. Zack JA, Kim SG, Vatakis DN. HIV restriction in quiescent CD4(+) T cells. Retrovirology. 2013;10:37.
97. Berro R, de la Fuente C, Klase Z, Kehn K, Parvin L, Pumfery A, et al. Identifying the membrane proteome of HIV-1 latently infected cells. J Biol Chem. 2007;282:8207–18.
98. Yang W, Zhou J-Y, Chen L, Ao M, Sun S, Aiyetan P, et al. Glycoproteomic analysis identifies human glycoproteins secreted from HIV latently infected T cells and reveals their presence in HIV+ plasma. Clin Proteome. 2014;11:9.
99. Britton LM, Sova P, Belisle S, Liu S, Chan EY, Katze MG, et al. A proteomic glimpse into the initial global epigenetic changes during HIV infection. Proteomics. 2014;14:2226–30.
100. Bartha I, McLaren PJ, Ciuffi A, Fellay J, Telenti A. GuavaH: a compendium of host genomic data in HIV biology and disease. Retrovirology. 2014;11:6.